Previous 10 | Next 10 |
Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review PR Newswire As Psycheceutical prepares to begin clinical trials for its novel NeuroDirect ™ ketamine topical to treat PTSD, the company is named to Life Science Review's year...
Psycheceutical Chief Visionary Officer Zappy Zapolin and CEO Chad Harman with MAPS Founder Rick Doblin MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge...
(NewsDirect) By Faith Ashmore, Benzinga Psycheceutical Bioscience, Inc (OTCPK: BWVI) is a biotechnology company with patented technology that says it aims to revolutionize the psychedelic mental health space and disrupt Big Pharma. The company is developing a topical cream administrat...
--News Direct-- By Faith Ashmore, Benzinga Psycheceutical Bioscience, Inc (OTCPK: BWVI) is a biotechnology company with patented technology that says it aims to revolutionize the psychedelic mental health space and disrupt Big Pharma. The company is developing a topical cream administ...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical cream Patients indicated their thought processes were clearer and more focused, and were ...
(NewsDirect) By Julian Richard, Benzinga When the average person thinks about psychedelics, it is easy to conjure up a picture of a trippy experience with hallucinogenic visions, and ‘Lucy In The Sky With Diamonds’ playing in the background. And if you aren’t familiar...
Psycheceutical Bioscience (OTC: BWVI) , a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, has entered into an exclusive agreement with iNGENū Pty Ltd., an Australian-based contract research organization. The agr...
Psycheceutical enters into agreement with iNGENū to conduct human clinical trials of NeuroDirect™ ketamine topical in Australia Phase I trial will study 20 people to test the safety, tolerability, and pharmacokinetics of a single d...
MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of mental health treatments, is pleased to announce it ...
MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Tra...
News, Short Squeeze, Breakout and More Instantly...
Blue Water Ventures Inc Company Name:
BWVI Stock Symbol:
OTCMKTS Market:
Blue Water Ventures Inc Website:
MIAMI, FL / ACCESSWIRE / May 16, 2024 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of neurological treatments, announces the Company's continued inability ...
The distress in the psychedelic space contributed to the Company's challenges. The inability of the Company to undertake certain corporate actions (name and symbol change etc.) due to regulatory filing deficiencies from over a decade ago has hampered the ability of the Company to reposition ...
MIAMI, FL / ACCESSWIRE / December 12, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of treatments for neurological diseases, is thrilled to announce th...